ClinicalTrials.gg
CompletedNCT06781632RopiCloBetUpdated May 18, 2025

Phase I Study of Ropivacaine, Clonidine, and Betamethasone Combination for Sciatic Nerve Block in the Popliteal Region

A Phase 1 interventional study of ropivacaine in Healthy and Nerve Block, sponsored by PHARMAFINA. Completed at 1 site in Turkey. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by PHARMAFINA · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a national, single-center, dose-escalation Phase I study to investigate the safety, pharmacokinetics, and efficacy of a combination containing Ropivacaine, Clonidine, and Betamethasone (Ropiclobet) in healty volunteers.

After screening and eligibility confirmation, at least 28 participants will receive a sciatic nerve block in the popliteal region with Ropiclobet, followed by pharmacokinetic assessments through blood sampling and monitoring of motor and sensory nerve blocks in the tibial and common peroneal nerves. Safety evaluations, including physical exams, vital signs, ECGs, and sedation scores, will be conducted throughout the study. sensory blocks resolve.

Participants will remain under observation for 48 hours post-procedure and will be discharged once motor and sensory blocks resolve. Follow-up visits will be conducted on Days 10 and 15 on an outpatient basis, with an end-of-study visit planned for Day 30.

The dose-escalation protocol involves administering 5 mL, 10 mL, 15 mL, and 20 mL doses to sequential groups of participants, with safety assessments performed after each dose level before proceeding.

Read the detailed description

This is a national, single-center, dose-escalation Phase I clinical study designed to evaluate the safety, pharmacokinetics, and efficacy of a novel combination drug containing Ropivacaine, Clonidine, and Betamethasone, referred to as Ropiclobet, in healthy adult volunteers. The primary objective is to assess the safety of Ropiclobet when administered as a sciatic nerve block in the popliteal region. Secondary objectives include monitoring the drug's efficacy in inducing motor and sensory nerve blockade and evaluating its pharmacokinetic profile through.

The study will begin with the enrollment of a minimum of 28 healthy volunteers who meet the predefined eligibility criteria. Once deemed eligible, participants will receive a sciatic nerve block in the popliteal region using the investigational combination drug Ropiclobet. To investigate the pharmacokinetics of Ropiclobet, blood samples will be collected from each volunteer at carefully scheduled time points post-administration. These samples will be analyzed to determine the plasma concentrations of the three active components: Ropivacaine, Clonidine, and Betamethasone. Concurrently, effects of the drug will be evaluated by monitoring motor and sensory nerve blockades, specifically targeting the two primary branches of the popliteal nerve: the tibial nerve and the common peroneal nerve. Sensory blockade assessments will include tests for pin-prick and temperature sensations, while motor block evaluation will involve standardized clinical examinations.

Throughout the study, comprehensive safety monitoring will be conducted. This includes regular physical examinations, continuous vital sign measurements, electrocardiograms (ECGs), and the assessment of sedation levels. Volunteers will remain under observation in the Phase I clinic for at least 48 hours post-procedure. Discharge from the clinic will only occur after confirmation that both motor and sensory blocks have fully resolved. If the blocks persist beyond the 48-hour observation window, participants will be discharged no later than six hours following the resolution of the blockades. In addition to in-clinic assessments, follow-up evaluations will be performed on Days 10 and 15 on an outpatient basis, with a comprehensive end-of-study visit scheduled for Day 30. These visits aim to identify any delayed adverse effects and to ensure the complete recovery of participants.

The study's dose-escalation protocol involves four predefined dose levels of Ropiclobet: 5 mL, 10 mL, 15 mL, and 20 mL. Initially, 4 volunteers will receive a 5 mL dose for the sciatic nerve block. After a 48-hour observation period, detailed safety assessments will determine whether it is safe to proceed to the next dose level. If the safety profile of the 5 mL dose is deemed acceptable, an additional 8 volunteers will receive a 10 mL dose. This stepwise approach will continue with escalating doses of 15 mL and 20 mL, with safety evaluations conducted at each level before advancing to the subsequent dose. The final dose of 20 mL will only be administered if safety parameters remain within acceptable limits throughout the study.

02

Conditions studied

  • Healthy
  • Nerve Block

Keywords

  • Ropivacaine
  • Clonidine
  • Betamethasone
  • Nerve Block
03

In context

Lead sponsor

PHARMAFINA is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers based on the results of medical evaluation, including medical history, physical examination, neurological examination, laboratory tests, and cardiac monitoring, performed by the investigator.
  • Between 18 and 45 years, male and female
  • Provide a signed and dated written
  • A negative pregnancy test at the screening visit for female volunteers with
  • Negative alcohol breath test.
  • Negative urine drug screening for addictive substances (amphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opioids).
  • Capable of completing all tests and evaluations related to the study.
  • In the investigator's opinion, the volunteer must have the potential to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  • Volunteers with to local anesthesia/regional anesthesia.
  • Volunteers with a known hypersensitivity to amide-based local anesthetics.
  • Volunteers with chronic pain.
  • Volunteers with neuromuscular diseases or peripheral neuropathy.
  • Volunteers with bleeding disorders/coagulopathies.
  • Volunteers with a history of motor or sensory loss in the lower extremities.
  • Volunteers with a history of arrhythmia or seizures.
  • Volunteers with renal or hepatic insufficiency.
  • Volunteers diagnosed with diabetes.
  • Volunteers with hereditary neuropathy.
  • Volunteers with a (BMI) > 35 kg/m².
  • Pregnant, breastfeeding, or women with a positive pregnancy test.
  • Volunteers with skin infections or wounds at the injection site.
  • Volunteers with abnormalities in the , such as rhythm, conduction, or morphology issues, or any abnormalities on a 12-lead ECG that could interfere with the interpretation of changes (including normal ST-T wave morphology or left ventricular hypertrophy), as determined by the investigator or medical monitor, or those on chronic use of antiarrhythmic medications.
  • Volunteers with clinically significant abnormalities in vital signs during screening, which may include:

    1. systolic blood pressure \< 90 or > 140 mmHg,
    2. diastolic blood pressure \< 50 or > 95 mmHg,
    3. heart rate \< 45 or > 100 beats/min, measured three times at 5-minute intervals in a seated position.
  • Volunteers with any condition (medical, psychological, social, etc.) that may impair their ability to comply with the study, as assessed by the investigator.
  • Volunteers currently participating in another clinical study.
  • Volunteers with a positive urine drug screening and/or alcohol test.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Nerve Block Arm

    Volunteers will undergo sciatic nerve block in the popliteal region using the combination drug Ropiclobet (Ropivacaine-Clonidine-Betamethasone)

    Drug: ropivacaine

Interventions

  • Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)

    Also known as: clonidine, betamethasone

06

What researchers measure

Primary outcomes

  1. Number of treatment-related adverse events assessed by NCI-CTCAE

    The incidence of treatment-related adverse events, measured according to NCI-CTCAE criteria.

    Time frame: From nerve block procedure to the end of study visit at 30 days

  2. Number of treatment-related adverse events assessed by laboratory parameters

    The incidence of treatment-related adverse events based on hematological, and biochemical parameters

    Time frame: Before nerve block procedure, 24 and 48 hours after procedure, and during follow-up visits on Day 10, Day 15, Day 30

  3. Number of treatment-related adverse events assessed by ECG

    The incidence of treatment-related adverse events based on electrocardiography

    Time frame: From nerve block procedure to discharge at 48 hours, and during follow-up visits on Day 10, Day 15, Day 30

  4. Number of treatment-related adverse events assessed by physical examination and vital signs

    The incidence of treatment-related adverse events based on physical examination and vital signs

    Time frame: From nerve block procedure to discharge at 48 hours, and during follow-up visits on Day 10, Day 15, Day 30

Secondary outcomes

  1. Pharmacokinetics (concentration analysis)

    The concentration-time profiles in plasma for each of the three active ingredients (Cmax)

    Time frame: before the sciatic nerve block (at 0.hour) and post-block at 15, 30, and 45 minutes, and at 1, 2, 3, 4, 6, 8, 12, 18, 24, and 48 hours.

  2. Pharmacokinetics (concentration analysis)

    The concentration-time profiles in plasma for each of the three active ingredients (Area under curve)

    Time frame: before the sciatic nerve block (at 0.hour) and post-block at 15, 30, and 45 minutes, and at 1, 2, 3, 4, 6, 8, 12, 18, 24, and 48 hours.

  3. Pharmacokinetics (concentration analysis)

    The concentration-time profiles in plasma for each of the three active ingredients (tmax)

    Time frame: before the sciatic nerve block (at 0.hour) and post-block at 15, 30, and 45 minutes, and at 1, 2, 3, 4, 6, 8, 12, 18, 24, and 48 hours.

  4. Efficacy of ropiclobet assessed by onset of motor block

    The time to the onset of complete motor block (in minutes or hours)

    Time frame: From nerve block procedure to the onset of motor block, up to 48 hours

  5. Efficacy of ropiclobet assessed by duration of motor block

    The time of resolution of the motor block (in minutes or hours)

    Time frame: From nerve block procedure to the resolution of the motor block, up to 48 hours

  6. Efficacy of ropiclobet assessed by onset of sensorial block

    The time to the onset of complete sensorial block (in minutes or hours)

    Time frame: From nerve block procedure to the onset of sensorial block, up to 48 hours

  7. Efficacy of ropiclobet assessed by duration of sensorial block

    The time of resolution of the sensorial block (in minutes or hours)

    Time frame: From nerve block procedure to the resolution of the sensorial block, up to 48 hours

  8. Efficacy ropiclobet assessed by duration of motor and sensorial block

    Total motor and sensorial block time (in minutes or hours)

    Time frame: From onset of motor and sensorial block to the resolution, up to 48 hours

07

Study locations

1 site
  • Istanbul University, Istanbul Faculty of Medicine Phase I and Clinical Research Center
    Istanbul, 34093, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Feb 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 17, 2025
StartActual
Nov 13, 2024
Primary completionActual
Feb 20, 2025
CompletionActual
Apr 25, 2025
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06781632
Lead sponsor
PHARMAFINA
Collaborators
MonitorCRO
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Nov 13, 2024
Primary completion
Feb 20, 2025
Completion
Apr 25, 2025
Last update
May 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion